Annual Report 2020

CHAIRMAN’S STATEMENT 7 The United Laboratories International Holdings Limited Annual Report 2020 On behalf of the board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”), I am pleased to present to all shareholders the annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2020. In 2020, the COVID-19 pandemic caused severe impacts on the global economy, exerted severe challenges to all industries, and the global supply chain therefore had been under tremendous pressure. Thanks to strict pandemic prevention and control measures, China quickly found its way out of the haze of the pandemic, and social production recovered rapidly. Meanwhile, supported by strong domestic demand, China has become the sole major economy in the world that recorded positive growth, with an increase in GDP of 2.3% as compared to 2019, demonstrating China’s strong economic capacity to withstand pressure. Since the pandemic outbreak, the national medical and health system has shown tremendous resilience and has played an important role in the battle against the pandemic. As a member of the pharmaceutical industry, the Group organised the resumption of work and production in an orderly manner under the premise of ensuring the health and safety of employees, and made positive contributions to maintain the stability of drug supply. The Group accumulatively donated more than RMB4 million and anti-epidemic materials worth nearly RMB1 million during the year to support epidemic prevention and control, and fulfilled corporate social responsibilities with practical actions. Mr. Tsoi Hoi Shan Chairman